LeonaBio
Share
We are dedicated to the development of novel therapeutics for diseases with high unmet needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patient’s lives. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is
01/09/2026
Today marks an important milestone for our company.
Athira Pharma is now LeonaBio, Inc., reflecting a transformative new chapter following our acquisition of rights to lasofoxifene, a Phase 3 program in metastatic breast cancer. Along with our new name, our Nasdaq ticker will change to LONA, effective January 12, 2026.
We remain dedicated to advancing innovative therapies for patients with serious diseases and high unmet medical need.
Read the full announcement: https://investors.athira.com/static-files/5a0c261e-d22b-4af9-87c7-bc15bda7315b
Click here to claim your Sponsored Listing.
Category
Contact the business
Website
Address
18706 North Creek Parkway, Suite 104
Seattle, WA
98011
